Dr. Volker M. Gorenflo, M.Eng., P.Eng., PMP

Experience

• 

  The University of British Columbia

  Jan 2002 - Jan 2004

  Research Faculty, Biotech Lab

  As part of the research faculty, I implemented cutting-edge technologies to enhance process performance and streamline virus and recombinant protein production, optimizing various production methods such as batch, fed batch, and perfusion.

• 

  Sanofi

  Jan 2004 - Jan 2007

  In this role, I utilized quality by design (QbD) and design of experiments (DoE) methodologies to develop, optimize, and scale up cell culture and bacterial processes, ensuring the highest quality standards and improved efficiency.

  • Senior Process Development Scientist, Lead Scientist

    Jan 2005 - Jan 2007

  • Process Development Scientist

    Jan 2004 - Jan 2005
• 

  Baxter Company Limited ( BCL )

  Jan 2007 - Jan 2010

  I served as Vaccines Development Lead (VDL) in R&D, leading Baxter’s cell culture-based influenza vaccine development in both the US and Europe. I also oversaw the entire process from clinical development to licensure and launched the vaccine in collaboration with manufacturing and commercial teams. In addition, I successfully forged partnerships with major US government contracts, including the US Department of Health and Human Services (DHHS).

  • Vaccines Development Lead

    Jan 2009 - Jan 2010

  • Global Project Leader

    Jan 2007 - Jan 2009
• 

  Novartis Animal Health

  Jan 2010 - Jan 2013

  As Head of Development, I managed technical and clinical advancements and oversaw program management (PMO) for the creation of fish vaccines and the transition to manufacturing. I effectively supervised diverse global teams and built a high-performing product development team.✦ Key Highlights ✦• Successfully led Aqua Biologics' product development portfolio. • Spearheaded the groundbreaking DNA vaccine, Clynay, through clinical and regulatory processes for submission to the European Medicines Agency (EMA) and European Commission (EC), making it the first DNA vaccine approved by EMA and EC. Show less

  • Head of Development

    Jan 2012 - Jan 2013

  • International R&D Manager, Aqua Biologics

    Jan 2011 - Jan 2012

  • International Project Leader

    Jan 2010 - Jan 2011
• 

  Novartis Vaccines and Diagnostics

  Jan 2013 - Jan 2015

  Director, Global Product Lead, Novartis Vaccines

  In this role, I oversaw Menveo and Menjugate vaccines’ product supply and a global LCM portfolio.

• 

  GSK

  Jan 2015 - Jan 2025

  Senior Director, Global Product Lead, GSK Vaccines

  As a senior director, I provide thought leadership and guidance to multiple teams consisting of 10 to 15 team members accountable for various aspects of business strategy, product launch, supply, and product life cycle projects across relevant GSK vaccine sites. I also demonstrate effective cross-functional leadership across diverse departments, including technical and clinical development. Additionally, I oversee a team of 2 direct reports and 4-5 direct reports during my interim role as Head of PMO in the portfolio management office of industrial operations. I also serve as the main point of contact for the global supply chain in vaccines commercialization and vaccines development teams. I also develop and implement effective product strategies for GSK vaccine's Meningitis and mRNA products.✦ Key Highlights ✦• Provide end-to-end leadership experience from pre-clinical development to manufacturing, commercialization, and supply.• Extensive experience in project and portfolio management, establishing a robust portfolio for Meningitis products, ensuring a stable supply, and eliminating backorders.• Collaborated with engineering and project management teams to design and validate state-of-the-art GMP facilities, including a new mRNA vaccine facility. • Successfully engaged with matrix and functional leaders. Show less